Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
Verywell Health on MSN15h
Navigating Care Through Every Phase of Metastatic Breast CancerIf you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.
Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...
The former Kate Middleton was diagnosed with cancer early in 2024, and much speculation about the state of her health has followed. Catherine, Princess of Wales, has since shared that she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback